PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33402456-5 2021 CK2 inhibition was performed using the specific inhibitor tetra-bromobenzotriazole (TBB). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 84-87 casein kinase 2, alpha prime polypeptide Mus musculus 0-3 31228268-7 2019 TBB has an inhibitory effect on casein kinase 2 (CK2), which phosphorylate STAT1 at serine residues. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 0-3 signal transducer and activator of transcription 1 Homo sapiens 75-80 33019973-6 2020 METHODS: The small particles loaded with FGF-2 were newly fabricated and incorporated into the commercial 4-META/MMA-TBB resin. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 117-120 fibroblast growth factor 2 Homo sapiens 41-46 32380794-7 2020 Inhibitors of CK2, such as TBB and the preclinical compound CX4549 (silmitasertib), also blocked membrane expression of TMEM16A and Ca2+-activated whole cell currents. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 27-30 anoctamin 1 Homo sapiens 120-127 31987502-3 2020 Here, we found that inhibition of casein kinase 2 (Csnk2) by TBB or DMAT was sufficient to block the reduction of the Tcf7l1 protein induced by CHIR99021, a specific inhibitor of GSK-3. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 61-64 transcription factor 7 like 1 (T cell specific, HMG box) Mus musculus 118-124 32218358-3 2020 Using tetrabromobenzotriazole (TBB) and 2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole (DMAT) as scaffolds for CK2 inhibition, and a hydroxamate to coordinate the zinc atom present in the active site of HDAC (zinc binding group, ZBG), new multitarget inhibitors have been designed and synthesized. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 31-34 histone deacetylase 9 Homo sapiens 205-209 32174814-6 2020 Western blot analyses demonstrated that CA1 tissue from TBB-pretreated epileptic animals contained significantly less CK2 than TBB-pretreated controls. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 127-130 carbonic anhydrase 1 Rattus norvegicus 40-43 32174814-7 2020 On the transcriptional level, TBB pretreatment led to differential gene expression changes of KCa2.2, but also of HCN1 and HCN3 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 30-33 potassium calcium-activated channel subfamily N member 2 Rattus norvegicus 94-100 32174814-7 2020 On the transcriptional level, TBB pretreatment led to differential gene expression changes of KCa2.2, but also of HCN1 and HCN3 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 30-33 hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 Rattus norvegicus 114-118 32174814-7 2020 On the transcriptional level, TBB pretreatment led to differential gene expression changes of KCa2.2, but also of HCN1 and HCN3 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 30-33 hyperpolarization-activated cyclic nucleotide-gated potassium channel 3 Rattus norvegicus 123-127 32174814-9 2020 Conclusion: These data indicate that TBB pretreatment prior to SE slows down disease progression during epileptogenesis involving increased KCa2 function, probably due to a persistently decreased CK2 protein expression. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 37-40 casein kinase 2 beta Rattus norvegicus 196-199 32692785-7 2020 We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 14-17 calcineurin binding protein 1 Homo sapiens 97-118 32692785-7 2020 We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 14-17 FYN proto-oncogene, Src family tyrosine kinase Homo sapiens 138-141 32692785-7 2020 We found that TBB (a casein kinase II inhibitor), AR and LiCl (GSK-3 inhibitors), cyclosporin A (calcineurin inhibitor), and Saracatinib (Fyn kinase inhibitor) caused robust inhibition of OA-induced monomeric and oligomeric p-tau in both N2a and CTX culture. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 14-17 microtubule associated protein tau Homo sapiens 226-229 32692785-9 2020 This study provides a comprehensive view of potential drug candidates (TBB, CsA, AR, and Saracatinib), and their efficacy against tau hyperphosphorylation and oligomerization processes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 71-74 microtubule associated protein tau Homo sapiens 130-133 32174814-2 2020 Previously, we observed that in vivo casein kinase 2 (CK2) inhibition with 4,5,6,7-tetrabromotriazole (TBB) had anti-epileptogenic effects in the acute epilepsy slice model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 103-106 casein kinase 2 beta Rattus norvegicus 37-52 32174814-2 2020 Previously, we observed that in vivo casein kinase 2 (CK2) inhibition with 4,5,6,7-tetrabromotriazole (TBB) had anti-epileptogenic effects in the acute epilepsy slice model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 103-106 casein kinase 2 beta Rattus norvegicus 54-57 32174814-6 2020 Western blot analyses demonstrated that CA1 tissue from TBB-pretreated epileptic animals contained significantly less CK2 than TBB-pretreated controls. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 carbonic anhydrase 1 Rattus norvegicus 40-43 32174814-6 2020 Western blot analyses demonstrated that CA1 tissue from TBB-pretreated epileptic animals contained significantly less CK2 than TBB-pretreated controls. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 casein kinase 2 beta Rattus norvegicus 118-121 30535443-5 2019 In addition, TBB reduced the expression of type II collagen and stimulated the accumulation of beta-catenin, phenotypic markers of chondrocyte differentiation and dedifferentiation, respectively. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 catenin beta 1 Homo sapiens 95-107 28993142-6 2018 Inhibitors for G-protein-regulated second messengers, such as Rp-cAMP, H89, TBB, ryanodine, and thapsigargin, unexpectedly enhanced GluN2B phosphorylation, suggesting that cAMP, PKA, casein kinase II, and cytosolic calcium signaling may oppose to the effect of ghrelin on the phosphorylation of GluN2B. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 76-79 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 132-138 30629065-5 2019 Unexpectedly, we were lucky to identify new and selective MMP13 inhibitors (10, IC50 = 3.7 nM and 11, IC50 = 5.6 nM) with a novel TBB-derived scaffold. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 130-133 matrix metallopeptidase 13 Homo sapiens 58-63 30219695-0 2018 Oral administration of the casein kinase 2 inhibitor TBB leads to persistent KCa2.2 channel up-regulation in the epileptic CA1 area and cortex, but lacks anti-seizure efficacy in the pilocarpine epilepsy model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 53-56 potassium calcium-activated channel subfamily N member 2 Rattus norvegicus 77-83 30219695-0 2018 Oral administration of the casein kinase 2 inhibitor TBB leads to persistent KCa2.2 channel up-regulation in the epileptic CA1 area and cortex, but lacks anti-seizure efficacy in the pilocarpine epilepsy model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 53-56 carbonic anhydrase 1 Rattus norvegicus 123-126 30219695-10 2018 Hence, our findings indicate that oral administration of TBB leads to persistent up-regulation of KCa2.2 in the epileptic CA1 subfield and in the neocortex, but lacks anti-seizure efficacy in the pilocarpine epilepsy model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 57-60 potassium calcium-activated channel subfamily N member 2 Rattus norvegicus 98-104 30219695-10 2018 Hence, our findings indicate that oral administration of TBB leads to persistent up-regulation of KCa2.2 in the epileptic CA1 subfield and in the neocortex, but lacks anti-seizure efficacy in the pilocarpine epilepsy model. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 57-60 carbonic anhydrase 1 Rattus norvegicus 122-125 30159756-7 2018 CK2 inhibitors (TBB and Ellagic acid), did not affect protection by S117A-FGF2 but prevented protection by mitogenic FGF2. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 16-19 casein kinase 2 beta Rattus norvegicus 0-3 30159756-7 2018 CK2 inhibitors (TBB and Ellagic acid), did not affect protection by S117A-FGF2 but prevented protection by mitogenic FGF2. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 16-19 fibroblast growth factor 2 Homo sapiens 117-121 29966873-1 2018 The new aminoalkyl-substituted derivatives of known CK2 inhibitors 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi) and 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) were synthesized, and their influence on the activity of recombinant human CK2 alpha, CK2 holoenzyme and PIM1 kinases was evaluated. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 114-149 casein kinase 2 alpha 2 Homo sapiens 232-241 29966873-1 2018 The new aminoalkyl-substituted derivatives of known CK2 inhibitors 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi) and 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) were synthesized, and their influence on the activity of recombinant human CK2 alpha, CK2 holoenzyme and PIM1 kinases was evaluated. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 114-149 Pim-1 proto-oncogene, serine/threonine kinase Homo sapiens 262-266 29760653-5 2018 We found that either Abeta treatment or tau overexpression stimulated CK2 activation leading to SET Ser9 hyperphosphorylation in neurons and animal models, while inhibition of CK2 by TBB abolished this event. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 183-186 casein kinase 2, alpha prime polypeptide Mus musculus 176-179 28993142-6 2018 Inhibitors for G-protein-regulated second messengers, such as Rp-cAMP, H89, TBB, ryanodine, and thapsigargin, unexpectedly enhanced GluN2B phosphorylation, suggesting that cAMP, PKA, casein kinase II, and cytosolic calcium signaling may oppose to the effect of ghrelin on the phosphorylation of GluN2B. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 76-79 glutamate ionotropic receptor NMDA type subunit 2B Rattus norvegicus 295-301 28603902-15 2017 The CKII inhibitor TBB, similar to the ERK5 inhibitor XMD8-92, specifically restrained PTEN phosphorylation, therefore suppressing Akt phosphorylation in human platelets treated with botrocetin/VWF. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 19-22 casein kinase 2 alpha 1 Homo sapiens 4-8 28111119-10 2017 Moreover, PD-L1 positivity between EBUS-TBNA and TBB (n = 16), TBB and the corresponding primary tumor (n = 41), and lymph node metastasis and the corresponding primary tumor (n = 47) showed a moderate correlation (all r > 0.48; all P < .001), strengthening the potential concordance between EBUS-TBNA and primary tumor in PD-L1 positivity. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 49-52 CD274 molecule Homo sapiens 10-15 28111119-10 2017 Moreover, PD-L1 positivity between EBUS-TBNA and TBB (n = 16), TBB and the corresponding primary tumor (n = 41), and lymph node metastasis and the corresponding primary tumor (n = 47) showed a moderate correlation (all r > 0.48; all P < .001), strengthening the potential concordance between EBUS-TBNA and primary tumor in PD-L1 positivity. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 63-66 CD274 molecule Homo sapiens 10-15 28743511-10 2017 Suppression of Raf-1 or CK2 by its inhibitor (GW5074 or TBB) blocked vimentin phosphorylation, remodeling and endothelial apoptosis, and preserved cell viability in TNF-alpha-induced HUVECs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 15-20 28743511-10 2017 Suppression of Raf-1 or CK2 by its inhibitor (GW5074 or TBB) blocked vimentin phosphorylation, remodeling and endothelial apoptosis, and preserved cell viability in TNF-alpha-induced HUVECs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 vimentin Homo sapiens 69-77 28743511-10 2017 Suppression of Raf-1 or CK2 by its inhibitor (GW5074 or TBB) blocked vimentin phosphorylation, remodeling and endothelial apoptosis, and preserved cell viability in TNF-alpha-induced HUVECs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 tumor necrosis factor Homo sapiens 165-174 28603902-15 2017 The CKII inhibitor TBB, similar to the ERK5 inhibitor XMD8-92, specifically restrained PTEN phosphorylation, therefore suppressing Akt phosphorylation in human platelets treated with botrocetin/VWF. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 19-22 phosphatase and tensin homolog Homo sapiens 87-91 28603902-15 2017 The CKII inhibitor TBB, similar to the ERK5 inhibitor XMD8-92, specifically restrained PTEN phosphorylation, therefore suppressing Akt phosphorylation in human platelets treated with botrocetin/VWF. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 19-22 AKT serine/threonine kinase 1 Homo sapiens 131-134 28603902-15 2017 The CKII inhibitor TBB, similar to the ERK5 inhibitor XMD8-92, specifically restrained PTEN phosphorylation, therefore suppressing Akt phosphorylation in human platelets treated with botrocetin/VWF. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 19-22 von Willebrand factor Homo sapiens 194-197 28989983-10 2017 Among mothers, we found a significant positive relation between house dust and handwipe BDE-209 and TBB + TBPH concentrations. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 100-103 homeobox D13 Homo sapiens 88-91 28496082-6 2017 TBB was performed again and the tumor was diagnosed as SCC. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 0-3 serpin family B member 3 Homo sapiens 55-58 27782092-7 2016 In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 229-232 casein kinase 2 beta Rattus norvegicus 125-128 28027904-11 2017 In addition, TBB (4, 5, 6, 7-tetrabromo-2-benzotriazole, a pharmacological inhibitor of CK2) blocked IL-6 release in a dose-dependent manner, whereas co-treatment of cells with EsA and TBB did not have an additive effect. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 casein kinase 2, alpha prime polypeptide Mus musculus 88-91 28027904-11 2017 In addition, TBB (4, 5, 6, 7-tetrabromo-2-benzotriazole, a pharmacological inhibitor of CK2) blocked IL-6 release in a dose-dependent manner, whereas co-treatment of cells with EsA and TBB did not have an additive effect. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 interleukin 6 Mus musculus 101-105 28027904-11 2017 In addition, TBB (4, 5, 6, 7-tetrabromo-2-benzotriazole, a pharmacological inhibitor of CK2) blocked IL-6 release in a dose-dependent manner, whereas co-treatment of cells with EsA and TBB did not have an additive effect. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 185-188 casein kinase 2, alpha prime polypeptide Mus musculus 88-91 27782092-7 2016 In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 229-232 casein kinase 2 beta Rattus norvegicus 125-128 27782092-7 2016 In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 229-232 casein kinase 2 beta Rattus norvegicus 125-128 27782092-8 2016 Moreover, both TBB and siRNA-mediated inhibition of CK2 blocked Ac2-26-mediated BV-2 microglia migration. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 casein kinase 2 beta Rattus norvegicus 52-55 26463037-5 2015 Thrombin-induced IL-8/CXCL8 release was inhibited by CK2 inhibitors (apigenin and tetrabromobenzotriazole, TBB), small interfering RNA of CK2beta (CK2beta siRNA), and MSK1 siRNA. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 107-110 coagulation factor II, thrombin Homo sapiens 0-8 27506419-6 2016 Moreover, there was significant up-regulation of CYP3A4 expression via PXR activation for TBB and TBPH and their metabolites. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 90-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-55 27506419-6 2016 Moreover, there was significant up-regulation of CYP3A4 expression via PXR activation for TBB and TBPH and their metabolites. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 90-93 nuclear receptor subfamily 1 group I member 2 Homo sapiens 71-74 26895417-8 2016 Moreover, in the TBB samples, the CD4 (+) IL-17(+ )Th17 and CD4(+) FoxP3(+ )Tregs numbers were significantly higher in SM and COPD patients than HC (p < 0.05). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 17-20 CD4 molecule Homo sapiens 34-37 26895417-8 2016 Moreover, in the TBB samples, the CD4 (+) IL-17(+ )Th17 and CD4(+) FoxP3(+ )Tregs numbers were significantly higher in SM and COPD patients than HC (p < 0.05). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 17-20 CD4 molecule Homo sapiens 60-63 26895417-8 2016 Moreover, in the TBB samples, the CD4 (+) IL-17(+ )Th17 and CD4(+) FoxP3(+ )Tregs numbers were significantly higher in SM and COPD patients than HC (p < 0.05). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 17-20 forkhead box P3 Homo sapiens 67-72 27116117-1 2016 We report a unique strategy to obtain the bifunctional heterogeneous catalyst TBB-Bpy@Salen-Co (TBB=1,2,4,5-tetrakis(bromomethyl)benzene, Bpy=4,4"-bipyridine, Salen-Co=N,N"-bis({4-dimethylamino}salicylidene)ethylenediamino cobalt(III) acetate) by combining a cross-linked ionic polymer with a Co(III) -salen Schiff base. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 78-81 mitochondrially encoded cytochrome c oxidase III Homo sapiens 230-233 27116117-1 2016 We report a unique strategy to obtain the bifunctional heterogeneous catalyst TBB-Bpy@Salen-Co (TBB=1,2,4,5-tetrakis(bromomethyl)benzene, Bpy=4,4"-bipyridine, Salen-Co=N,N"-bis({4-dimethylamino}salicylidene)ethylenediamino cobalt(III) acetate) by combining a cross-linked ionic polymer with a Co(III) -salen Schiff base. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 78-81 mitochondrially encoded cytochrome c oxidase III Homo sapiens 293-300 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 fibroblast growth factor 14 Mus musculus 68-73 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 neuron navigator 1 Mus musculus 74-78 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 casein kinase 2, alpha prime polypeptide Mus musculus 151-166 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 casein kinase 2, alpha prime polypeptide Mus musculus 168-171 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 fibroblast growth factor 14 Mus musculus 210-215 26917740-4 2016 Bioluminescence-based screening of small molecule modulators of the FGF14:Nav1.6 complex identified 4,5,6,7 -: tetrabromobenzotriazole (TBB), a potent casein kinase 2 (CK2) inhibitor, as a strong suppressor of FGF14:Nav1.6 interaction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 136-139 neuron navigator 1 Mus musculus 216-220 26917740-5 2016 Inhibition of CK2 through TBB reduces the interaction of FGF14 with Nav1.6 and Nav1.2 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 26-29 casein kinase 2, alpha prime polypeptide Mus musculus 14-17 26917740-5 2016 Inhibition of CK2 through TBB reduces the interaction of FGF14 with Nav1.6 and Nav1.2 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 26-29 fibroblast growth factor 14 Mus musculus 57-62 26917740-5 2016 Inhibition of CK2 through TBB reduces the interaction of FGF14 with Nav1.6 and Nav1.2 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 26-29 neuron navigator 1 Mus musculus 68-72 26917740-5 2016 Inhibition of CK2 through TBB reduces the interaction of FGF14 with Nav1.6 and Nav1.2 channels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 26-29 sodium channel, voltage-gated, type II, alpha Mus musculus 79-85 26917740-7 2016 In 1 d in vitro hippocampal neurons, TBB induced a reduction in FGF14 expression, a decrease in transient Na(+) current amplitude, and a hyperpolarizing shift in the voltage dependence of Nav channel steady-state inactivation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 37-40 fibroblast growth factor 14 Mus musculus 64-69 26917740-8 2016 In mature neurons, TBB reduces the axodendritic polarity of FGF14. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 19-22 fibroblast growth factor 14 Mus musculus 60-65 26917740-10 2016 Importantly, these changes in excitability are recapitulated in Fgf14(-/-) mice, and deletion of Fgf14 occludes TBB-dependent phenotypes observed in wild-type mice. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 112-115 fibroblast growth factor 14 Mus musculus 97-102 26463037-5 2015 Thrombin-induced IL-8/CXCL8 release was inhibited by CK2 inhibitors (apigenin and tetrabromobenzotriazole, TBB), small interfering RNA of CK2beta (CK2beta siRNA), and MSK1 siRNA. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 107-110 C-X-C motif chemokine ligand 8 Homo sapiens 17-21 26463037-5 2015 Thrombin-induced IL-8/CXCL8 release was inhibited by CK2 inhibitors (apigenin and tetrabromobenzotriazole, TBB), small interfering RNA of CK2beta (CK2beta siRNA), and MSK1 siRNA. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 107-110 C-X-C motif chemokine ligand 8 Homo sapiens 22-27 25891901-1 2015 The interaction of human CK2alpha (hCK2alpha) with nine halogenated benzotriazoles, TBBt and its analogues representing all possible patterns of halogenation on the benzene ring of benzotriazole, was studied by biophysical methods. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 84-88 casein kinase 2 alpha 2 Homo sapiens 25-33 25891901-1 2015 The interaction of human CK2alpha (hCK2alpha) with nine halogenated benzotriazoles, TBBt and its analogues representing all possible patterns of halogenation on the benzene ring of benzotriazole, was studied by biophysical methods. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 84-88 casein kinase 2 alpha 2 Homo sapiens 35-44 25957086-8 2015 CK2 inhibition by TBB also attenuated IGFBP-1 phosphorylation in leucine deprivation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 18-21 insulin like growth factor binding protein 1 Homo sapiens 38-45 24596964-4 2014 RESULTS: Chronic oral administration of the CK2 inhibitor 4,5,6,7-tetrabromotriazole (TBB) for 4 days prior to brain dissection caused a significant increase of the sAHP-mediating current in both control and epileptic tissues. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 86-89 casein kinase 2 beta Rattus norvegicus 44-47 24431397-4 2015 CK2 signalling was inhibited by the selective CK2 inhibitor 4, 5, 6, 7-Tetrabromobenzotriazole (TBB). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 96-99 casein kinase 2, alpha prime polypeptide Mus musculus 0-3 24431397-4 2015 CK2 signalling was inhibited by the selective CK2 inhibitor 4, 5, 6, 7-Tetrabromobenzotriazole (TBB). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 96-99 casein kinase 2, alpha prime polypeptide Mus musculus 46-49 24431397-7 2015 Inhibition of CK2 by TBB abrogated the TGFbeta-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFbeta on collagen release and myofibroblasts differentiation in cultured fibroblasts. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 21-24 casein kinase 2, alpha prime polypeptide Mus musculus 14-17 24431397-7 2015 Inhibition of CK2 by TBB abrogated the TGFbeta-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFbeta on collagen release and myofibroblasts differentiation in cultured fibroblasts. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 21-24 transforming growth factor beta 1 Homo sapiens 39-46 24431397-7 2015 Inhibition of CK2 by TBB abrogated the TGFbeta-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFbeta on collagen release and myofibroblasts differentiation in cultured fibroblasts. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 21-24 Janus kinase 2 Homo sapiens 69-73 24431397-7 2015 Inhibition of CK2 by TBB abrogated the TGFbeta-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFbeta on collagen release and myofibroblasts differentiation in cultured fibroblasts. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 21-24 signal transducer and activator of transcription 3 Homo sapiens 74-79 24431397-7 2015 Inhibition of CK2 by TBB abrogated the TGFbeta-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFbeta on collagen release and myofibroblasts differentiation in cultured fibroblasts. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 21-24 transforming growth factor beta 1 Homo sapiens 132-139 24431397-10 2015 The antifibrotic effects of TBB were accompanied by reduced activation of JAK2/STAT3 signalling in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 28-31 Janus kinase 2 Homo sapiens 74-78 24431397-10 2015 The antifibrotic effects of TBB were accompanied by reduced activation of JAK2/STAT3 signalling in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 28-31 signal transducer and activator of transcription 3 Homo sapiens 79-84 25816228-3 2015 The trait of human infectivity in Tbr is conferred by a single gene, SRA, which is potentially transferable to the animal pathogen Tbb by sexual reproduction. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 131-134 steroid receptor RNA activator 1 Homo sapiens 69-72 25450618-1 2015 The interaction of human CK2alpha with a series of tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) analogs, in which one of the bromine atoms proximal to the triazole/imidazole ring is replaced by a methyl group, was studied by biochemical (IC50) and biophysical methods (thermal stability of protein-ligand complex monitored by DSC and fluorescence). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 76-80 casein kinase 2 alpha 2 Homo sapiens 25-33 24466573-5 2014 TBB did not affect sex-steroid production in this cell model; rather the data suggest a flux towards synthesis of aldosterone and cortisol via up-regulation of CYP21A2. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 0-3 cytochrome P450 family 21 subfamily A member 2 Homo sapiens 160-167 24596964-5 2014 In contrast, when TBB was acutely applied during the patch-clamp recording, the sAHP remained unaltered, indicating that chronic CK2 inhibition was required for sAHP augmentation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 18-21 casein kinase 2 beta Rattus norvegicus 129-132 24596964-7 2014 It is important to note that chronic oral TBB administration abolished REDs induced by 0-Mg2+ solution, suggesting that CK2 inhibition indeed has anticonvulsive and perhaps antiepileptogenic properties. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 42-45 casein kinase 2 beta Rattus norvegicus 120-123 24398405-5 2014 Treatment with TBB inhibited the 7-ketocholesterol-induced decrease in Bid, Bcl-2 and survivin protein levels, increase in Bax levels, loss of the mitochondrial transmembrane potential, cytochrome c release, activation of caspases (-8, -9 and -3), cleavage of PARP-1, and increase in the tumor suppressor p53 levels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 BH3 interacting domain death agonist Rattus norvegicus 71-74 24398405-5 2014 Treatment with TBB inhibited the 7-ketocholesterol-induced decrease in Bid, Bcl-2 and survivin protein levels, increase in Bax levels, loss of the mitochondrial transmembrane potential, cytochrome c release, activation of caspases (-8, -9 and -3), cleavage of PARP-1, and increase in the tumor suppressor p53 levels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 BCL2, apoptosis regulator Rattus norvegicus 76-81 24398405-5 2014 Treatment with TBB inhibited the 7-ketocholesterol-induced decrease in Bid, Bcl-2 and survivin protein levels, increase in Bax levels, loss of the mitochondrial transmembrane potential, cytochrome c release, activation of caspases (-8, -9 and -3), cleavage of PARP-1, and increase in the tumor suppressor p53 levels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 BCL2 associated X, apoptosis regulator Rattus norvegicus 123-126 24398405-5 2014 Treatment with TBB inhibited the 7-ketocholesterol-induced decrease in Bid, Bcl-2 and survivin protein levels, increase in Bax levels, loss of the mitochondrial transmembrane potential, cytochrome c release, activation of caspases (-8, -9 and -3), cleavage of PARP-1, and increase in the tumor suppressor p53 levels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 poly (ADP-ribose) polymerase 1 Rattus norvegicus 260-266 24398405-5 2014 Treatment with TBB inhibited the 7-ketocholesterol-induced decrease in Bid, Bcl-2 and survivin protein levels, increase in Bax levels, loss of the mitochondrial transmembrane potential, cytochrome c release, activation of caspases (-8, -9 and -3), cleavage of PARP-1, and increase in the tumor suppressor p53 levels. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 15-18 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 305-308 22499119-7 2012 In fact, TBB, a specific inhibitor of CK2, abolished the effects of NaHS. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 9-12 casein kinase 2 beta Rattus norvegicus 38-41 21553855-3 2011 The yield of DHAP formed by intramolecular transfer of hydrogen decreases from 49% for the muscle enzymes to 40% for wildtype Tbb TIM to 34% for monoTIM. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 126-129 triosephosphate isomerase Oryctolagus cuniculus 130-133 23155426-5 2012 The role of halogen bonding remains debatable, as originally noted for the crystal structure of TBBt with CK2alpha (pdb1j91). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 96-100 casein kinase 2 alpha 2 Homo sapiens 106-114 21936567-7 2011 Furthermore, phosphorylation of EEF1D in the presence of TBB or TBBz is restored using CK2 inhibitor-resistant mutants. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 59-62 eukaryotic translation elongation factor 1 delta Homo sapiens 33-38 21620683-0 2011 The protein kinase CK2 inhibitor TBB mediates up-regulation of MEK3/6 and p38delta activities, down-regulation of ERK1/2 activity and induction of G1/S arrest in normal human epidermal autocrine proliferating keratinocytes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 33-36 mitogen-activated protein kinase kinase 3 Homo sapiens 63-69 21620683-0 2011 The protein kinase CK2 inhibitor TBB mediates up-regulation of MEK3/6 and p38delta activities, down-regulation of ERK1/2 activity and induction of G1/S arrest in normal human epidermal autocrine proliferating keratinocytes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 33-36 mitogen-activated protein kinase 13 Homo sapiens 74-82 21620683-0 2011 The protein kinase CK2 inhibitor TBB mediates up-regulation of MEK3/6 and p38delta activities, down-regulation of ERK1/2 activity and induction of G1/S arrest in normal human epidermal autocrine proliferating keratinocytes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 33-36 mitogen-activated protein kinase 3 Homo sapiens 114-120 21553855-5 2011 Product yields for the wildtype Tbb TIM and monoTIM-catalyzed reactions of glycolaldehyde labeled with carbon-13 at the carbonyl carbon ([1-(13)C]-GA) at pD 7.0 in the presence of phosphite dianion and in its absence were determined by (1)H NMR spectroscopy [Go, M. K., Amyes, T. L., and Richard, J. P. (2009) Biochemistry 48, 5769-5778]. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 32-35 triosephosphate isomerase Oryctolagus cuniculus 36-39 21553855-7 2011 The kinetic parameters for phosphite dianion activation of the reactions of [1-(13)C]-GA catalyzed by wildtype Tbb TIM are similar to those reported for the enzyme from rabbit muscle [Amyes, T. L. and Richard, J. P. (2007) Biochemistry 46, 5841-5854], but there is no detectable dianion activation of the reaction catalyzed by monoTIM. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 111-114 triosephosphate isomerase Oryctolagus cuniculus 115-118 20576813-8 2010 CK2 inhibitors (4,5,6,7-tetrabromo-1H-benzotriazole, apigenin, and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazol) decreased phosphorylation of PTEN and Akt, induced apoptosis in CLL cells, and enhanced the response to fludarabine. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 16-51 phosphatase and tensin homolog Homo sapiens 145-149 21125314-11 2011 Western analyses showed that TBB and TBCA elicited a significant (about twofold) increase in the activation of p38 and ERK1/2 MAP kinases that may be involved in cytoskeleton regulation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 29-32 mitogen-activated protein kinase 1 Homo sapiens 111-114 21125314-11 2011 Western analyses showed that TBB and TBCA elicited a significant (about twofold) increase in the activation of p38 and ERK1/2 MAP kinases that may be involved in cytoskeleton regulation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 29-32 mitogen-activated protein kinase 3 Homo sapiens 119-125 20576813-8 2010 CK2 inhibitors (4,5,6,7-tetrabromo-1H-benzotriazole, apigenin, and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazol) decreased phosphorylation of PTEN and Akt, induced apoptosis in CLL cells, and enhanced the response to fludarabine. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 16-51 AKT serine/threonine kinase 1 Homo sapiens 154-157 19875192-7 2010 CONCLUSION: Assessment of MRP1 and LRP mRNA expression in TBB specimens may predict histopathologic response and survival in locally advanced NSCLC patients who received neoadjuvant cisplatin-based chemotherapy. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 19875192-7 2010 CONCLUSION: Assessment of MRP1 and LRP mRNA expression in TBB specimens may predict histopathologic response and survival in locally advanced NSCLC patients who received neoadjuvant cisplatin-based chemotherapy. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 58-61 major vault protein Homo sapiens 35-38 19900859-9 2009 CONCLUSION: Our data suggested that determination of MRP1, LRP, and ERCC1 mRNA expression using RT-PCR in TBB samples might be helpful in predicting outcome of patients with advanced NSCLC treated with cisplatin-based chemotherapy and in optimizing therapeutic strategy based on the expression of these genes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 19760628-7 2010 RESULTS: Inhibition of CK2 by TBB led to a decrease in cell viability and apoptosis in two cell lines which express wild-type p53 whereas two other cell lines expressing mutant or no p53 failed to show signs of apoptosis. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 30-33 tumor protein p53 Homo sapiens 126-129 19900859-9 2009 CONCLUSION: Our data suggested that determination of MRP1, LRP, and ERCC1 mRNA expression using RT-PCR in TBB samples might be helpful in predicting outcome of patients with advanced NSCLC treated with cisplatin-based chemotherapy and in optimizing therapeutic strategy based on the expression of these genes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 106-109 major vault protein Homo sapiens 59-62 19900859-9 2009 CONCLUSION: Our data suggested that determination of MRP1, LRP, and ERCC1 mRNA expression using RT-PCR in TBB samples might be helpful in predicting outcome of patients with advanced NSCLC treated with cisplatin-based chemotherapy and in optimizing therapeutic strategy based on the expression of these genes. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 106-109 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 68-73 19583760-7 2009 The additional use of MP-11 primer significantly improved the bond strengths in the etch-and-rinse systems with 4-META/MMA-TBB resin. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 123-126 non-compact myelin associated protein Homo sapiens 22-27 19432557-8 2009 Tested on Jurkat cells, quinalizarin proved able to inhibit endogenous CK2 and to induce apoptosis more efficiently than the commonly used CK2 inhibitors TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 154-157 casein kinase 2, alpha prime polypeptide Mus musculus 139-142 19460754-7 2009 CK2 is the likely in vivo CAPS protein kinase based on inhibition of phosphorylation by tetrabromo-2-benzotriazole in PC12 cells and by the identity of in vivo and in vitro phosphorylation sites. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 88-114 casein kinase 2 beta Rattus norvegicus 0-3 19460754-7 2009 CK2 is the likely in vivo CAPS protein kinase based on inhibition of phosphorylation by tetrabromo-2-benzotriazole in PC12 cells and by the identity of in vivo and in vitro phosphorylation sites. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 88-114 calcium dependent secretion activator Rattus norvegicus 26-30 19787270-3 2009 Here we show that the protein kinase CK2 inhibitors DMAT, TBB and resorufin differ in their selectivity against PI3K family members, since PI3K and DNA-PK are subject to inhibition by DMAT and TBB, however, not by resorufin. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 58-61 protein kinase, DNA-activated, catalytic subunit Homo sapiens 148-154 19787270-3 2009 Here we show that the protein kinase CK2 inhibitors DMAT, TBB and resorufin differ in their selectivity against PI3K family members, since PI3K and DNA-PK are subject to inhibition by DMAT and TBB, however, not by resorufin. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 193-196 protein kinase, DNA-activated, catalytic subunit Homo sapiens 148-154 19787270-4 2009 TBB and DMAT treatment together with cisplatin lead to an inhibition of cisplatin-induced stress signaling (as detected by phosphorylation of JNK and H2AX). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 0-3 mitogen-activated protein kinase 8 Homo sapiens 142-145 19787270-4 2009 TBB and DMAT treatment together with cisplatin lead to an inhibition of cisplatin-induced stress signaling (as detected by phosphorylation of JNK and H2AX). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 0-3 H2A.X variant histone Homo sapiens 150-154 18258654-9 2008 Exploitation of an unbiased chemoproteomics approach revealed a number of putative off-target inhibitor interactions, including the discovery of a novel TBBz and DMAT (but not TBB) target, the detoxification enzyme quinone reductase 2 (QR2). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 153-156 N-ribosyldihydronicotinamide:quinone reductase 2 Homo sapiens 236-239 18588507-5 2008 In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 casein kinase 2, alpha prime polypeptide Mus musculus 56-59 18588507-5 2008 In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 proviral integration site 1 Mus musculus 87-91 18588507-5 2008 In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 13-16 proviral integration site 3 Mus musculus 96-100 18258654-6 2008 Utilizing a chemoproteomics approach in conjunction with inhibitor-resistant mutant studies, CK2alpha and CK2alpha" were identified as bona fide targets of TBB, TBBz, and DMAT in cells. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 156-159 casein kinase 2 alpha 2 Homo sapiens 93-101 18258654-6 2008 Utilizing a chemoproteomics approach in conjunction with inhibitor-resistant mutant studies, CK2alpha and CK2alpha" were identified as bona fide targets of TBB, TBBz, and DMAT in cells. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 156-159 casein kinase 2 alpha 2 Homo sapiens 106-114 18588507-2 2008 The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 56-59 casein kinase 2, alpha prime polypeptide Mus musculus 40-43 18588507-2 2008 The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 61-96 casein kinase 2, alpha prime polypeptide Mus musculus 40-43 17935135-7 2008 Using TBB, an inhibitor of protein kinase CK2, we showed that CK2 was required for hypoxia-induced HDAC activation. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 6-9 histone deacetylase 9 Homo sapiens 99-103 18265947-8 2008 Interactions between CK2 subunits and Svf1 protein may have influence on ATP as well as ATP-competitive inhibitors (TBBt and TBBz) binding. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 116-120 Svf1p Saccharomyces cerevisiae S288C 38-42 17935135-12 2008 Use of Apicidin (an HDAC inhibitor) and TBB revealed that CK2-dependent HDAC activation contributed to pVHL downregulation and HIF-1alpha stabilization under hypoxia. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 40-43 histone deacetylase 9 Homo sapiens 72-76 15630699-14 2005 An SPN diagnostic approach that includes a TBB, then PCNA, clinical observation, repeat CT scans, and repeat biopsies for continued suspicion of malignancy appears to reduce the unnecessary surgical excision of benign nodules from the current rate of 60% to 5% of SPN resections without affecting the survival of patients who have malignant SPNs. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 43-46 DEAF1 transcription factor Homo sapiens 3-6 17935135-12 2008 Use of Apicidin (an HDAC inhibitor) and TBB revealed that CK2-dependent HDAC activation contributed to pVHL downregulation and HIF-1alpha stabilization under hypoxia. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 40-43 von Hippel-Lindau tumor suppressor Homo sapiens 103-107 17935135-12 2008 Use of Apicidin (an HDAC inhibitor) and TBB revealed that CK2-dependent HDAC activation contributed to pVHL downregulation and HIF-1alpha stabilization under hypoxia. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 40-43 hypoxia inducible factor 1 subunit alpha Homo sapiens 127-137 17714183-7 2007 Treatment of FeCl2-exposed cells with CK2 inhibitors (DRB or TBB) led to decreased formation of alpha-Syn inclusions, oligomers and P alpha-Syn. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 61-64 synuclein alpha Homo sapiens 96-105 18214043-10 2007 These results suggest that immunostaining of MRP2 for TBB specimens may help to predict clinical resistance to platinum agents. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 54-57 ATP binding cassette subfamily C member 2 Homo sapiens 45-49 17573504-10 2007 CONCLUSIONS: The position of the probe (ie, within or adjacent to the PPL) is a significant factor in predicting the diagnostic yield of TBB using EBUS-GS for small PPLs; the optimum number of biopsy specimens is at least five. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 137-140 periplakin Homo sapiens 70-73 17714183-7 2007 Treatment of FeCl2-exposed cells with CK2 inhibitors (DRB or TBB) led to decreased formation of alpha-Syn inclusions, oligomers and P alpha-Syn. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 61-64 synuclein alpha Homo sapiens 134-143 17113388-7 2006 Remarkably, treatment of cells with TBB, a pharmaceutical inhibitor of CK2, blocked the recruitment and cycling of beta-catenin and TLE1 at Wnt target genes in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 36-39 catenin beta 1 Homo sapiens 115-127 17113388-7 2006 Remarkably, treatment of cells with TBB, a pharmaceutical inhibitor of CK2, blocked the recruitment and cycling of beta-catenin and TLE1 at Wnt target genes in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 36-39 TLE family member 1, transcriptional corepressor Homo sapiens 132-136 11604527-0 2001 Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 95-121 Calcium-dependent protein kinase 6 Zea mays 70-73 16411567-11 2005 CONCLUSIONS: The decreased level of catalase may point to its possible inactivation by metabolites of HBB, TBB and 1,4-dBB. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 107-110 catalase Rattus norvegicus 36-44 14985113-3 2004 We show here that Geminin is an excellent substrate for protein kinase CK2 in vitro; and that the highly specific CK2 inhibitor tetrabromobenzotriazole (TBB) blocks the phosphorylation of Geminin in HeLa protein extracts and HeLa cells in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 153-156 geminin DNA replication inhibitor Homo sapiens 18-25 14985113-3 2004 We show here that Geminin is an excellent substrate for protein kinase CK2 in vitro; and that the highly specific CK2 inhibitor tetrabromobenzotriazole (TBB) blocks the phosphorylation of Geminin in HeLa protein extracts and HeLa cells in vivo. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 153-156 geminin DNA replication inhibitor Homo sapiens 188-195 10099585-3 1999 CS2 removal rate data obtained in a TBB with a Thiobacilii consortia biofilm are analyzed to obtain the mass transfer and kinetic parameters, and to show that the bioreactor operates in a regime mainly controlled by mass transfer. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 36-39 chorionic somatomammotropin hormone 2 Homo sapiens 0-3 9372681-3 1997 The CD4/CD8 ratio of the TBB-clones had also increased, but this increase did not reach the level of that of the BAL clones. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 25-28 CD4 molecule Homo sapiens 4-7 9372681-3 1997 The CD4/CD8 ratio of the TBB-clones had also increased, but this increase did not reach the level of that of the BAL clones. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 25-28 CD8a molecule Homo sapiens 8-11 9372681-8 1997 Differences in the V beta percentages between BAL and TBB and the lower CD4/CD8 ratio in the TBB, however, demonstrate a relative independence of the two compartments. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 93-96 CD4 molecule Homo sapiens 72-75 9815799-11 1997 These results indicate that p53 overexpression in TBB specimens predicts poor prognosis and chemoresistance in advanced stage NSCLC. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 50-53 tumor protein p53 Homo sapiens 28-31 9701419-8 1998 The findings correlated well with the degree of monoclonal staining for MPO in TBB. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 79-82 myeloperoxidase Homo sapiens 72-75 8503549-8 1993 High dose corticosteroid treatment of ALR caused a fall in cellularity of BAL and TBB specimens but not always to values seen when patients were well. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 82-85 growth factor, augmenter of liver regeneration Homo sapiens 38-41 8503549-10 1993 HLA-DR and IL-2R expression was enhanced in cells of BAL and TBB in all complications. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 61-64 interleukin 2 receptor subunit alpha Homo sapiens 11-16 35143200-3 2022 In line with this trending research topic, the current paper highlights the development of tetrazole derivatives bearing a bisphenol structure (TbB) as a novel weak binder or potential inactive to the estrogen receptor (ER) and androgen receptor (AR). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 144-147 estrogen receptor 1 Homo sapiens 201-218 35143200-3 2022 In line with this trending research topic, the current paper highlights the development of tetrazole derivatives bearing a bisphenol structure (TbB) as a novel weak binder or potential inactive to the estrogen receptor (ER) and androgen receptor (AR). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 144-147 estrogen receptor 1 Homo sapiens 220-222 35143200-3 2022 In line with this trending research topic, the current paper highlights the development of tetrazole derivatives bearing a bisphenol structure (TbB) as a novel weak binder or potential inactive to the estrogen receptor (ER) and androgen receptor (AR). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 144-147 androgen receptor Homo sapiens 228-245 35143200-3 2022 In line with this trending research topic, the current paper highlights the development of tetrazole derivatives bearing a bisphenol structure (TbB) as a novel weak binder or potential inactive to the estrogen receptor (ER) and androgen receptor (AR). 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 144-147 androgen receptor Homo sapiens 247-249 35143200-7 2022 As these TbB ligands did not meet the established acceptance criteria of 50% inhibition, they are considered as extremely weak binders to ERalpha. 2-ethylhexyl 2,3,4,5-tetrabromobenzoate 9-12 estrogen receptor 1 Homo sapiens 138-145